Conference abstract · 24 Oct 2018
Conference abstractPublished 27 Jun 2016
Evaluating Immunogenicity in Biosimilars
BBCR Consulting, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Adoption of biosimilars is increasingly attractive to payers around the globe due to the mounting financial pressure from high expenditures on medical treatments. Clinical evaluation of comparative immunogenicity constitutes an important component of the regulatory review for biosimilar candidates. The anti-drug antibody formations are interpreted, during the review process, in relation to pharmacokinetics, pharmacodynamics, efficacy, and safety parameters. Evaluation of the immunogenicity associated with the biosimilar includes its negative impact on clinical relevant outcomes compared with the innovator product. Unwanted immunogenicity may lead to clinical consequences such as reduced or loss of efficacy, altered pharmacokinetics (PK), general immune and hypersensitivity reactions, and neutralisation of the natural counterpart (e.g. the physiological hormone). Relevant areas of discussion are: testing strategies for immunogenicity assessment; and scientific progress on the product-related factors that may contribute to the development of immunogenicity, in particular that are related to protein aggregation and post-translational modifications. For chronic administration products, immunogenicity monitoring is required for a 12-month period of continuous treatment. Furthermore, the anti-drug antibody titers (i.e., erythropoietin, growth hormone, follitropin-alfa) interpretation is influenced by product quality differences and supported by a single-dose comparative pharmacokinetic study in healthy volunteers. The acceptance margins of detected ADA incidence for the biosimilar candidate versus the innovator product have not yet been defined by EU regulators. Indeed, until now, there is no standard bioanalytical assay sensitivity adopted nor any generalization has been made on the negative influence of clinical evidence on ADA incidence. In conclusion, immunogenicity and ADA evaluation are both complex processes that start during pre-clinical comparability and continue throughout pre approval and post-approval monitoring.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Jun 2016
Immunogenicity of biosimilars
Conference abstract · 26 Oct 2015
Cost- Effective clinical trial design to detect immunogenicity and efficacy differences between biosimilar and innovator product.
Conference abstract · 2018
A PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTICENTRE, CLINICAL TRIAL TO EVALUATE THE IMMUNOGENICITY, SAFETY AND EFFICACY OF WOCKHARDTS BIOSIMILAR INSULIN GLARGINE (GLARITUS) WITH REFERENCE INSULIN GLARGINE (LANTUS) IN TYPE 2 DIABETES MELLITUS
Conference abstract · 6 Dec 2018
Preclinical evaluation of the immunogenicity of a new Cuban pneumococcal conjugate vaccine (PCV10) administered concomitantly with Heberpenta®-L vaccine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Candida Fratazzi”
